Contineum Therapeutics Inc (NASDAQ: CTNM) is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics. The company has no approved products and generates no product revenue, operating entirely on capital raised through equity financing while advancing its pipeline through clinical trials. Contineum completed its IPO no earlier than 2024, qualifying as an emerging growth company under the JOBS Act with that status set to expire no later than December 31, 2029 (per the 10-K filed 2026-03-05). The company is subject to FDA oversight in the United States and comparable regulatory bodies internationally, including the European Medicines Agency and the UK's MHRA, before any product can be commercialized. With no revenue base and a balance sheet composed primarily of cash, cash equivalents, and marketable securities as of December 31, 2025, Contineum is pre-revenue and dependent on continued external financing to fund operations and clinical development activities.

Revenue model

Contineum has no commercial revenue as of December 31, 2025. The company is pre-revenue and funds operations through equity capital markets. No product royalties, licensing fees, or collaboration payments are disclosed in the filing excerpts.

Products and services

Contineum is developing small molecule drug candidates in clinical-stage trials. No approved products are disclosed in the filing excerpts. The pipeline requires FDA approval in the United States and equivalent regulatory authorization in the EU and UK before any commercialization.

Customers and end markets

As a clinical-stage company with no approved products as of December 31, 2025, Contineum has no commercial customers. Target end markets are not specified in the filing excerpts provided.

Value-chain role

Contineum occupies an early-stage drug discovery and clinical development role in the biopharmaceutical value chain. It conducts clinical trials, interfaces with regulatory agencies including the FDA, EMA, and MHRA, and handles personal and health data subject to HIPAA, CCPA, and GDPR compliance obligations.

Geographic exposure

Contineum is subject to U.S. regulatory requirements and anticipates seeking approval in the EU and UK for any future products. No commercial geographic revenue split is available given pre-revenue status as of December 31, 2025.

Source: SEC 10-K, filed 2026-03-05

Industry: Pharmaceutical Preparations Peers: Aquestive Therapeutics Inc Pacira Biosciences Inc Eli Lilly and Co Esperion Therapeutics Inc EyePoint Inc Fulcrum Therapeutics Inc Definium Therapeutics Inc Terns Pharmaceuticals Inc Xeris Biopharma Holdings Inc Third Harmonic Bio, Inc.